{"id":"NCT01699178","sponsor":"Clarus Therapeutics, Inc.","briefTitle":"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men","officialTitle":"Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-10-03","resultsPosted":"2018-10-30","lastUpdate":"2021-06-28"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Oral testosterone undecanoate","otherNames":["Oral TU"]},{"type":"DRUG","name":"Transdermal testosterone gel (AndroGel)","otherNames":["AndroGel"]}],"arms":[{"label":"Oral testosterone undecanoate","type":"EXPERIMENTAL"},{"label":"Transdermal testosterone gel (AndroGel)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.","primaryOutcome":{"measure":"Absolute Change From Baseline in T Cholesterol","timeFrame":"Approximately 365 days","effectByArm":[{"arm":"Oral TU","deltaMin":0.2,"sd":null},{"arm":"Transdermal T-gel","deltaMin":8.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States","Germany"]},"refs":{"pmids":["36272969"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":88},"commonTop":["Polycythemia","Bronchitis","Hematocrit Increased","Rash","Hypertension"]}}